WallStreetZenWallStreetZen

NASDAQ: ABIO
Arca Biopharma Inc Stock

$3.50+0.24 (+7.36%)
Updated Jun 21, 2024
ABIO Price
$3.50
Fair Value Price
$2.58
Market Cap
$50.78M
52 Week Low
$1.56
52 Week High
$4.49
P/E
-8.33x
P/B
1.45x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.00M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$5M
Beta
0.45
Next Earnings
Jul 19, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ABIO Overview

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ABIO ($3.50) is overvalued by 35.81% relative to our estimate of its Fair Value price of $2.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABIO ($3.50) is not significantly undervalued (35.81%) relative to our estimate of its Fair Value price of $2.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABIO due diligence checks available for Premium users.

Be the first to know about important ABIO news, forecast changes, insider trades & much more!

ABIO News

Valuation

ABIO fair value

Fair Value of ABIO stock based on Discounted Cash Flow (DCF)
Price
$3.50
Fair Value
$2.58
Overvalued by
35.81%
ABIO ($3.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABIO ($3.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ABIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.33x
Industry
-5.75x
Market
30.75x

ABIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.45x
Industry
6.2x
ABIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ABIO's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
ABIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$36.7M
Liabilities
$1.6M
Debt to equity
0.05
ABIO's short-term assets ($36.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABIO's short-term assets ($36.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
$0.0
Financing
$0.0
ABIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ABIO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ABIO$50.78M+7.36%-8.33x1.45x
CLNN$50.86M+1.28%-0.86x11.93x
DYAI$51.46M-2.49%-6.29x11.39x
BRNS$51.52M+5.60%-0.72x0.30x
CASI$48.96M+4.57%-1.81x2.03x

Arca Biopharma Stock FAQ

What is Arca Biopharma's quote symbol?

(NASDAQ: ABIO) Arca Biopharma trades on the NASDAQ under the ticker symbol ABIO. Arca Biopharma stock quotes can also be displayed as NASDAQ: ABIO.

If you're new to stock investing, here's how to buy Arca Biopharma stock.

What is the 52 week high and low for Arca Biopharma (NASDAQ: ABIO)?

(NASDAQ: ABIO) Arca Biopharma's 52-week high was $4.49, and its 52-week low was $1.56. It is currently -22.05% from its 52-week high and 124.36% from its 52-week low.

How much is Arca Biopharma stock worth today?

(NASDAQ: ABIO) Arca Biopharma currently has 14,507,143 outstanding shares. With Arca Biopharma stock trading at $3.50 per share, the total value of Arca Biopharma stock (market capitalization) is $50.78M.

Arca Biopharma stock was originally listed at a price of $436,817.24 in Dec 31, 1997. If you had invested in Arca Biopharma stock at $436,817.24, your return over the last 26 years would have been -100%, for an annualized return of -36.32% (not including any dividends or dividend reinvestments).

How much is Arca Biopharma's stock price per share?

(NASDAQ: ABIO) Arca Biopharma stock price per share is $3.50 today (as of Jun 21, 2024).

What is Arca Biopharma's Market Cap?

(NASDAQ: ABIO) Arca Biopharma's market cap is $50.78M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arca Biopharma's market cap is calculated by multiplying ABIO's current stock price of $3.50 by ABIO's total outstanding shares of 14,507,143.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.